Zai Lab (US) LLC
1440 O’Brien Drive
About Zai Lab (US) LLC
Zai Lab is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China’s pharmaceutical market and address unmet medical needs, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.
For additional information about the company, please visit www.zailaboratory.com.
Stock Symbol: ZLAB
Stock Exchange: NYSE
11 articles with Zai Lab (US) LLC
Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
Turning Point Therapeutics, Inc. and Zai Lab announced topline data for repotrectinib within the China region from the previously disclosed Phase 1/2 TRIDENT-1 study dataset.
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
Zai Lab, a China-focused biopharma company that focuses on treatments for cancer and autoimmune diseases, announced positive data for its clinical trial on Zejula (niraparib) for ovarian cancer.
The SEC said that Yum China, BeiGene, Zai Lab, HutchMed and ACM Research are all at risk if they do not give U.S. regulators access to their audit records.
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Here’s a look at a few of the industry expansions that have been announced so far this month.
Zai Lab Limited calls itself a growing global biopharmaceutical company and is continuing to live up to that claim with its latest expansion announcement.
Here’s a run-down of some of the most recent collaboration announcements this week.
12/4/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.